Related Experiment Video
Updated: Mar 7, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Mineralocorticoid receptor antagonists in elderly patients with heart failure: a systematic review and meta-analysis
Deepa Japp1, Anoop Shah2, Sheila Fisken3
1Medicine of the Elderly, Western General Hospital Ringgold Standard Institution, Edinburgh EH4 2XU, UK.
Background:
Mineralocorticoid receptor antagonists (MRAs) improve outcomes in several populations of patients with heart failure (HF), but there has been no systematic review of MRAs in older patients.
Objectives:
Systematic review and meta-analysis of the efficacy and safety of MRA treatment in elderly HF patients.
Data Sources:
Trials were identified through a literature search until 24 January 2015.
Study Selection:
Randomised controlled trials (RCTs) of MRAs in patients with HF and/or left ventricular systolic dysfunction aged ≥65 years, with subgroup analysis of patients ≥65 years or with mean participant age ≥70 years.
Data Extraction And Synthesis:
Efficacy outcomes were mortality, hospitalisation for cardiovascular causes, symptom status or functional capacity. Safety outcomes were hyperkalaemia and renal dysfunction. Data were analysed using relative risk ratios with 95% confidence intervals. Relative risk ratios were pooled where more than three estimates were available.
Results:
Seven RCTs were included (total n = 8,638). Three RCTs in HF with reduced ejection fraction (HEFREF) reported overall benefit from MRA therapy with no significant treatment interaction for age; the effects of MRAs on mortality in patients ≥75 years displayed marked inter-study heterogeneity. In four RCTs of HF with preserved ejection fraction (HEFPEF), MRA treatment had no significant effect on any efficacy outcome.
Conclusion:
MRAs improve clinical outcomes in selected cohorts of older patients with HEFREF but not HEFPEF. In patients ≥75 years with HEFREF, the effect of MRA treatment on overall mortality is uncertain. Further study is required in subgroups of elderly patients with both HEFREF and HEFPEF.